Clinical trial
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell…
NCT00075751 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075751 |
|---|---|
| Title | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, carboplatin, bortezomib |
| Enrollment | 99 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 13, 2004 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: